683 Capital Management’s Neuropace NPCE Stock Holding History

683 Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-24,933	Closed	-$257K	–	222
2023 Q4	$257K	Buy	+24,933	New	+$199K	0.02%	146

Other funds holding NPCE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

KLC

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

683 Capital Management's NPCE Position: Q1 2024 in Review

683 Capital Management sold out of Neuropace (NPCE) in Q1 2024, closing a stake of 24,933 shares — an estimated $257K sold.

683 Capital Management first reported a position in NPCE in Q4 2023 and held it in 1 quarter. The position peaked at $257K in Q4 2023. 54 funds tracked by Wall St. Rank hold NPCE as of Q1 2024.

683 Capital Management reported no remaining Neuropace position as of Q1 2024 after selling out during the quarter.
683 Capital Management sold 24,933 Neuropace shares in Q1 2024, an estimated $257K.
683 Capital Management first reported a position in Neuropace in Q4 2023 and held it in 1 quarter.
683 Capital Management's Neuropace position peaked at $257K in Q4 2023.
54 funds tracked by Wall St. Rank held Neuropace as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.